{"disease":{"id":"cerebral-av-malformation","name":"cerebral av malformation"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03467295","title":"Treatments and Outcomes of Untreated Cerebral Cavernous Malformations in CHina.","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"First Affiliated Hospital of Fujian Medical University","has_results":false},{"nct_id":"NCT04467489","title":"Biomarkers of CASH","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1040,"lead_sponsor_name":"University of Chicago","has_results":false},{"nct_id":"NCT03652181","title":"CASH (Cavernous Angiomas With Symptomatic Hemorrhage) Trial Readiness","phase":"","overall_status":"COMPLETED","enrollment_count":123,"lead_sponsor_name":"University of Chicago","has_results":true},{"nct_id":"NCT06983132","title":"Natural History of Familial Cerebral Cavernous Malformations: the CCM_Italia Cohort Study","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","has_results":false},{"nct_id":"NCT02603328","title":"Atorvastatin Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"University of Chicago","has_results":true},{"nct_id":"NCT03589014","title":"Treat_CCM: Propranolol in Familial Cerebral Cavernous Malformation","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":71,"lead_sponsor_name":"Mario Negri Institute for Pharmacological Research","has_results":false},{"nct_id":"NCT05085561","title":"The Symptomatic Cerebral Cavernous Malformation Trial of REC-994","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Recursion Pharmaceuticals Inc.","has_results":false},{"nct_id":"NCT06264531","title":"Efficacy and Safety of Anti-angiogenic Therapy With IV Bevacizumab in Patients With Symptomatic Cerebral Arteriovenous Malformations","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"Fondation Ophtalmologique Adolphe de Rothschild","has_results":false},{"nct_id":"NCT03341039","title":"PHIL Evaluation in the Endovascular Treatment of Intracranial Cerebral ArterioVenous Malformation (cAVM)","phase":"","overall_status":"TERMINATED","enrollment_count":20,"lead_sponsor_name":"Microvention-Terumo, Inc.","has_results":false},{"nct_id":"NCT05148663","title":"CCM Blood Biomarker Validation Study","phase":"","overall_status":"TERMINATED","enrollment_count":12,"lead_sponsor_name":"Texas Tech University Health Sciences Center, El Paso","has_results":false},{"nct_id":"NCT05298709","title":"Functional Magnetic Resonance Imaging (fMRI) Vascular Reactivity in Cerebral Cavernous Malformations (CCM)","phase":"NA","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"University of New Mexico","has_results":false},{"nct_id":"NCT03474614","title":"Effect of Oral Propranolol on mRNA Expresssion in Symptomatic Cavernous Malformation","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"St. Joseph's Hospital and Medical Center, Phoenix","has_results":false}],"total":12},"guidelines":[],"source":"Drug Landscape verified database"}